BLNDX
Price
$16.85
Change
+$0.15 (+0.90%)
Updated
Jun 11 closing price
Net Assets
843.48M
NLSAX
Price
$19.91
Change
-$0.00 (-0.00%)
Updated
Jun 12 closing price
Net Assets
7.62B
Interact to see
Advertisement

BLNDX vs NLSAX

Header iconBLNDX vs NLSAX Comparison
Open Charts BLNDX vs NLSAXBanner chart's image
BLNDX vs NLSAX Comparison Chart in %
View a ticker or compare two or three
VS
BLNDX vs. NLSAX commentary
Jun 13, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BLNDX is a Buy and NLSAX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
NLSAX has more cash in the bank: 7.62B vs. BLNDX (843M). BLNDX pays higher dividends than NLSAX: BLNDX (0.64) vs NLSAX (0.00). BLNDX was incepted earlier than NLSAX: BLNDX (6 years) vs NLSAX (14 years). NLSAX (1.64) is less costly to investors than BLNDX (1.39). BLNDX is a more actively managed with annual turnover of: 11.00 vs. NLSAX (0.96). NLSAX has a lower initial minimum investment than BLNDX: NLSAX (1000) vs BLNDX (25000). BLNDX annual gain was more profitable for investors over the last year : 28.21 vs. NLSAX (4.57). BLNDX return over 5 years is better than : 43.72 vs. NLSAX (18.22).
BLNDXNLSAXBLNDX / NLSAX
Total Expense Ratio1.261.6477%
Annual Report Gross Expense Ratio1.391.6485%
Fund Existence6 years14 years-
Gain YTD13.9280.9631,446%
Front LoadN/A6%-
Min. Initial Investment2500010002,500%
Min. Initial Investment IRAN/AN/A-
Net Assets843M7.62B11%
Annual Yield % from dividends0.640.00-
Returns for 1 year28.214.57618%
Returns for 3 years31.2321.90143%
Returns for 5 years43.7218.22240%
Returns for 10 yearsN/A56.44-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CVGRX49.830.04
+0.08%
Calamos Growth A
PHPSX30.73N/A
N/A
ProFunds Pharmaceuticals UltraSector Svc
SILVX18.95N/A
N/A
SGI US Large Cap Equity I
FNGDX15.81N/A
N/A
Franklin Intl Growth C
MRGAX52.64N/A
N/A
MFS Core Equity A